exCalibur 1

exCalibur 1

EXCALIBUR1 is a three-armed RCT randomizing between 1) systemic chemotherapy + Liver-Tx, 2) systemic chemotherapy + HAI-Floxuridine, 3) Systemic chemotherapy – current standard treatment.

Including patients  < 70 yrs with inoperable colorectal livermetastases who have progressed on current line chemotherapy and are hence planned for next line treatment. (see inclusion/exclusion-criteria).

Following MDT potentially eligible patients will be evaluated at Rikshospitalet, Oslo University Hospital. If found eligible for inclusion and consent for participation patients will be randomized.

Liver-Tx: If randomized to Liver-Tx patients are to start next line chemotherapy at their local hospital importantly without avastin. The patients will shortly after randomization be admitted to department of Transplantationsurgery at Oslo University Hospital (OUH) for full pre-Tx workup. Thereafter they are listed for extended criteria Liver-Tx. While waiting for Tx patients will continue systemic chemotherapy with a CT Chest and abdomen every 8 weeks. The patients are followed by the study-group with Quality Of Life (QoL) every 8 weeks. If progression the patients will be treated according to current guidelines and best clinical practice. They are not taken out of study. If progression beyond the possibility for Liver-Tx the patients will be unlisted and continue treatment as recommended by their treating oncologist. If/when liver-Tx is complete the patients will be followed by their local oncologist and department of transplantationsurgery, OUH.

HAI-Floxurudine: If randomized to HAI-Floxuridine patients will shortly after inclusion be given a date for operation for implantation of the chemo-pump. (Tricumed 1200V). The catheter is placed in the gastroduodenalartery via laparotomy and the pump is placed subcutaneously on the patients abdomen. The pump is filled with heparinized NaCl. Day 3-5 after operation a angiography and scintigraphy is performed to verify liver-only distribution of pump-content. Postoperative care as normal after laparotomy and discharged to home. Day 14 after pump-placement the patients meet at the outpatient-clinic, OUH, for the first cycle of Floxuridine. Day 28 after pump-placement the patients return to outpatient-clinic, OUH for emptying of the pump and installation of heparinized NaCl. At this time the patients will also start systemic chemotherapy at their local hospital. The pump-treatment is repeated every 28 days (14 days Floxuridine in pump and 14 days heparinized NaCl). Every 8 weeks the patients are followed with QoL and CT-chest and abdomen and evaluated at MDT,OUH.

Radiographic examinations will routinely be performed at local hospital.

Side-effects HAI-Floxuridine:  Floxuridine has a 100% first-pass metabolism in the liver and is generally well tolerated with little side-effects. Serious side-effects will first and foremost be due to extra-hepatic distribution of Floxuridine eg gastritis, gastric/duodenal ulcers, and pancreatitis. Therefore all patients are prescribed PPI`s and should continue PPI`s throughout the course of the pump-treatment. Secondly side-effects may be due to the catheter causing hepatic artery thrombosis or aneurism.

If any of the above mentioned conditions are diagnosed the pump-treatment will be stopped immediately. Therefore included patients with abdominal pain should seek immediate medical assistance for further investigation and the study-group consulted without delay.

Systemic chemotherapy: Patients randomized to systemic chemotherapy will start next line chemotherapy at their local hospital. Blood-tests and clinical work-up will be obtained at their local-hospital every 14 days and collected by the study-group. Every 8 weeks (4 cycles) a CT-chest + abdomen will be taken and evaluated by MDT,OUH. QoL will be taken every 8 weeks.

Inclusion and Exclusion criteria

Included patients must fulfil the following criteria

1. Primary histology: verified adenocarcinoma in colon or rectum

2. Liver metastases

a. Not possible or feasible to resect at time of inclusion.
b. Resection will require 10 % or more response in index lesions.
c. And one of the following:

    • Insufficient response on current line chemotherapy and in need of next line systemic chemotherapy or major change of active agents as judget by treating oncologist.
    • Treatment stopped due to toxicity, and hence in need of next line systemic chemotherapy.

3. Chemotherapy

a. Patients must have received at least one line of systemic chemotherapy at time of inclusion in the study. Planned for next line chemotherapy.
b. If patients have commenced next line chemotherapy, randomization can only be allowed prior to first evaluation on next line chemotherapy regimen.

4. The patient

a. Good performance status, ECOG 0 or 1.
b. Satisfactory blood tests: Hb >9 g/dl, neutrophiles >1.0 (after any G-CSF), TRC >75, Bilirubin<1.5 x upper normal level, ASAT, ALAT<5 x upper normal level, Creatinine <1.25 x upper normal level. Albumin above lower normal level.

5. Signed informed consent and expected cooperation of the patients for treatment and follow up must be obtained and documented according to GCP, and national/local regulations.


Exclusion Criteria

Any of the following criteria will exclude participation in the trial:

1. Arterial anatomy not suited for HAI pump-line insertion.
2. A primary tumour in situ that is either a

a. Rectal tumour scheduled for radiation therapy with fractionation 2 Gy x 25, or
b. A right-sided or transverse colonic tumour

3. Previous or current bone or CNS metastatic disease.
4. Patients with known intolerance or allergy to any ingredient of the IMP to be used as standard therapy for that patient
5. Breastfeeding women
6. Patients with a psychiatric condition that makes participation in the trial impossible or unethical
7. Patients in a poor nutritional state, those with depressed bone marrow function or those with potentially serious infections must be excluded.

8. Any other reason why, in the opinion of the investigators, the patient should not participate.
9. BRAF positivity

10. Any sign of extra-hepatic metastatic disease or local recurrence on PET/CT scan, and on CT or MRI thorax/abdomen/pelvis dated within 6 weeks prior to the trial hospital MDT meeting (exception allowed for <3 resectable lung lesions all < 15mm).
11. Liver lesion >10cm

12. Patient BMI > 30

13. Any previous non colorectal malignancy within latest five years
14. Age > 70 years

15. Liver metastatic ingrowth to the diaphragm determined by CT-scan and/or MRI/or ultrasound
16. Any primary tumour in situ